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http://dx.doi.org/10s an alternative in the cancer treatment. The objec-
tive of this study was to assess the oncologic outcomes, sexual function, and the sexual behavior of
men treated by PB for a cancer of the penis.
METHODS AND MATERIALS: Between 1992 and 2009, 47 patients with a cancer of the penis
were treated by PB (192Ir), in the Toulouse, Montpellier, and Barcelona cancer centers. The inves-
tigation into their sexuality was obtained by means of questionnaire. A total of 21 French patients
were approached, of whom 19 (mean age5 73.2 years) agreed to answer the questionnaire (partic-
ipation rate5 90.5%).
RESULTS: Oncologic data: The specific survival and the disease-free survival at 5 years was
87.6% (95% confidence interval, 72.4e94.7%) and 84% (95% confidence interval, 57.6e94.7%),
respectively. The rate of preservation of the penis was 66% (n5 31). Sexual data: Among the 17
patients sexually active before brachytherapy, 10 patients remained sexually active after treatment
(58.8%). Of the 18 patients who had erections before PB, 17 still had them after treatment (94.4%).
Age was the main predictive factor.
CONCLUSION: The PB seems to have a moderated impact on the sexual functions and the sexual
behavior of the patients.  2014 American Brachytherapy Society. Published by Elsevier Inc.
Open access under CC BY-NC-ND license.Keywords: Penile carcinoma; Brachytherapy; IIEF score; Oncological dataIntroduction
Penile carcinoma accounts for 0.4e0.6% of all malig-
nant neoplasms among men in Europe (1, 2). Its incidence
may reach 20% in some Asian, African, and South Amer-
ican countries.
Penile cancer is a disease of elderly men in Europe and
North America, with a peak incidence in the sixth decade of
life (3), although it may affect a younger age group inuary 2013; received in revised form 13 May 2013;
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.1016/j.brachy.2013.06.001developing countries. Most tumors of the penis are squa-
mous cell carcinomas and occur most commonly on the
glans, prepuce, and the coronal sulcus.
For small lesions, treatment enabling the penis body to
be preserved, notably penis brachytherapy (PB) (4), is rec-
ommended to improve the quality of life. Surprisingly,
sexuality, which is nevertheless an important component
of the quality of life in men with cancer, has not been well
studied after conservative treatment of penile cancer. By
analyzing a previous series of 51 patients treated between
1971 and 1989, we obtained information about the persis-
tence of sexuality and penile erections of patients (5), but
we did not have access to information on the impact of
PB on all sexual functions and sexual behavior. To answer
these questions, we established a database in the Catalan
and Occitan Oncology Group, which includes two cancer
centers each in France and Spain. We analyzed theOpen access under CC BY-NC-ND license.
Table 1
Characteristics of the tumors
Parameters Classification N (%)
Histology
T1 33 (70.2)
T2 5 (10.6)
Unknown 9 (19.2)
Grade
Well differentiated 28 (59.6)
Moderate differentiation 3 (6.4)
Low differentiation 3 (4.3)
Unknown 14 (29.7)
Size (mm)
!20 18 (38.3)
20e30 13 (27.7)
O30 1 (2.1)
Unknown 15 (31.9)
Pathology
Epidermoid carcinoma 43 (91.5)
Spinocellular carcinoma 3 (6.4)
Cuniculatum carcinoma 1 (2.1)
Localization
Glans 43 (91.5)
Body 4 (8.5)
Table 2
Brachytherapy parameters
Parameters Mean Minimum Maximum
Wires number 5 2 8
Dose (Gy) 60 42 70
Dose rate (cGy/h) 80 35 161
Active length (mm) 32.7 20 45
Gy5 unit dose delivered by implantation.
381B. Delaunay et al. / Brachytherapy 13 (2014) 380e387oncologic outcome of penile cancer, and conducted a survey
by questionnaire on the sexual functions and behavior after
PB treatment, in the two French centers.Methods and materials
Population and treatment modalities
Between 1992 and 2009, 47 patients were treated for
cancer of the penis by interstitial PB in the centers of Tou-
louse (Institut Claudius Regaud, n5 31), Montpellier
(Centre Val D’Aurelle, n5 4), and Barcelona (Catalan
Institute of Oncology and Hospital de Sant Pau, n5 12).
At the time of PB, the mean age of the patients was 64.7
years (range, 38e84 years). The tumor characteristics are
summarized in Table 1. None of the patients had palpable
lymph nodes on initial physical examination. The treatment
consisted in all cases of exclusive PB, low dose rate, with
manual implantation of 192Ir. All uncircumcised patients
had been circumcised before treatment. A Foley catheter
was left in place until removal of the sources. The param-
eters of PB are summarized in Table 2.
Sexuality questionnaire
To evaluate not only the sexual function but also the
sexual behavior of patients after treatment, we used the grid
BASIC IDEA of Lazarus (6) and Cottraux et al. (7) that
addresses nine areas, namely Behavior (B), Affect (A),
Sensation (S), Imagery (I), Cognition (C), Interpersonal
(I), Drugs (D), Expectation (E), and Attitude (A). A pretest
was conducted among 5 patients who underwent surgery
for phimosis after the age of 60 years. In common withthe studied population, these patients were of the same
age and had a similar history of disease of the terminal area
of the penis (a history of inflammation). The final question-
naire includes 31 questions and takes about 20 min to be
completed by the patient. The survey on sexuality also used
the validated French version of the International Index of
Erectile Function (IIEF) questionnaire that explores five
domains (desire, erection, orgasm, satisfaction from sexual
relations, and overall satisfaction).
In June 2010, we conducted a survey on sexuality among
21 French patients in remission from their disease. After
sending a newsletter, it was proposed to the patients that
they complete the questionnaire on sexuality. Patients were
considered as accepting to participate in the survey if they
filled out the questionnaire. The study was approved by our
Institutional Research Board. Finally, we obtained the
participation of 19 of the 21 patients (90.5%). The partici-
pation of the patients is detailed in Fig. 1.Statistical analysis
The software used for the statistical data was Stata (Sta-
ta, Corp., College Station, TX). The c2 test or Fisher exact
test (F ) were used for comparison of qualitative variables.
The ManneWhitney, Wilcoxon, or KruskaleWallis tests
were used for the comparison of the distributions of quan-
titative variables. The Spearman rank test was used to
assess the correlation between quantitative variables.
Survival tables were designed for each type of survival
(overall, specific, and recurrence free), and were used to
assess survival at different times of followup. Survival anal-
ysis was performed using the KaplaneMeier method.Results
Oncologic results (n5 47)
Approximately 80 months after PB (12.8e189.8), 28
patients (59.6%) showed no recurrence, 16 (34%) experi-
enced a local recurrence that required a partial (n5 15)
or total amputation (n5 1), and 8 (17%) had regional
and/or distant recurrence. The rate of preservation of the
penis was 66% (n5 31). At the time of our survey, 23
(48.9%) patients were cured without recurrence, 10
(21.3%) were cured after treatment of local recurrence, 8
Fig. 1. Population participating in the survey on sexual functions and behaviors.
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causes (Fig. 2).
The overall survival at 2 and 5 years was 86.4% (95%
confidence interval [CI], 72.1e93.6%) and 80.9% (95%
CI, 65.2e90%), respectively (Fig. 3). The specific survival
at 2 and 5 years was 90.7% (95% CI, 77.1e96.4%) and
87.6% (95% CI, 72.4e94.7%), respectively (Fig. 4). The
disease-free survival at 2 and 5 years was 90.5% (95%
CI, 67e97.5%) and 84% (95% CI, 57.6e94.7%), respec-
tively (Fig. 5).
Patients with a tumor in the penis body had a signifi-
cantly higher risk of recurrence (regional/distant) than
those with glans tumors ( p5 0.013; ManneWhitney test
and Fisher test). In contrast, lesion size, stage, histologic
type, and grade do not emerge as prognostic factors of
local, regional, and distant recurrence, despite a nonsignifi-
cant tendency for patients with squamous cell carcinoma
( p5 0.074).
Survey on sexuality (n5 19)
The average age of the population was 73.2 years (range,
45e89 years). A total of 17 patients (89.5%) were sexually
active before treatment (Table 3), with 78.9% reporting no
erectile dysfunction.Sexuality after treatment
A total of 10 (58.8%) of 17 patients remained sexually
active before and after treatment (Table 4). Around 7
(36.8%) patients had no erectile dysfunction, 8 (42.1%)
had frequent erections, 15 (78.9%) maintained nocturnal
erections, and 10 (58.8%) rated their erections as ‘‘hard’’
or ‘‘almost hard.’’ None of the men in the study suggested
a loss of manliness. Nine men (47.3%) felt that PB had not
changed their sexuality, and three (15.8%) evoked mild
changes. A total of 10 men (52.6%) observed modifications
in the glans sensitivity.
Among the patients who continued to have sexual inter-
course, 8 (80%) maintained orgasms. The average age of
sexual partner was 66.6 years (median5 70 years; range,
37e85 years). The average duration of cohabitation was
38.2 years (median, 40 years; minimum, 4 years; maximum,
67 years). A total of 11 (57.9%) of the 19 men felt that sexu-
ality was between ‘‘very important’’ to ‘‘moderately impor-
tant’’ to their partner. A total of 12 men (63.1%) felt that
they had between a ‘‘very good’’ (n5 8) or ‘‘good’’
(n5 4) communication about sexuality with their partners.
Concerning the consequences of PB on the sexuality, six
men (31.6%) noted that they were ‘‘well informed,’’ but six
(31.6%) and seven declared to be ‘‘poorly informed’’ and
Fig. 2. Status of the overall population at the date of the survey.
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their sexual partner were correlated with the frequency of
sexual intercourse ( p5 0.032 and 0.019, respectively).
Patients who felt that PB had little or no changes in their
sexuality had an IIEF-5 score ( p5 0.016), IIEF-15
( p5 0.003), and a frequency of sexual intercourse
( p5 0.026) significantly higher. We found no significant
correlation among the sexuality items and the parameters
of PB (dose, dose rate, number of needles, and active
length), and the tumor size. The level of sexual desire
was correlated with the frequency of sexual intercourseFig. 3. KaplaneMeier representation of the global survival.before ( p5 0.0498) and after treatment ( p5 0.0009),
and to the satisfaction of sexual intercourse
( p5 0.00001). The age of the patient and their partner
were correlated with the level of sexual desire
( p5 0.0093 and 0.0113, respectively). Changes in sensi-
tivity of the glans, the discomfort or the appearance of
the penis, pain, and ulceration were not significantly related
to changes in sexuality. Nonsexual morbidity is described
in Table 5. After PB, 73.7% of patients had ‘‘no’’ or ‘‘little’’
pain. One patient had ‘‘frequent’’ bleeding, and the rate of
frequency of meatal stenosis was 21.1%.Fig. 4. KaplaneMeier representation of the specific survival.
Fig. 5. KaplaneMeier representation of the disease-free survival.
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By analyzing a previous series of 51 patients treated
between 1971 and 1989, Delannes et al. (5) had concluded
that apart from a patient who developed painful erections
because of penile sclerosis, ‘‘sexual function did not appear
to be altered by the implant.’’ Little information is provided
in the literature on the effects of PB on sexual behavior. All
the studies evoked the persistence of sexuality after PB (8,
9), but they did not provide an answer to the impact of PB
on all sexual functions and the sexual behavior of treated
men. This present study is the first detailed assessment of
sexuality in this population. The men treated with PB are
a potential target population for the sexual function and
behavior study.
A total of 89.5% of patients in our series had sexual
intercourse before treatment, although the median age atTable 3
Pretreatment sexual functions
Parameters Classification N (%)
Sexual intercourse
Often 7 (36.9)
Sometimes 5 (26.3)
Rarely 5 (26.3)
Never 2 (10.5)
Erectile dysfunction
Often 1 (5.3)
Sometimes 1 (5.3)
Rarely 2 (10.5)
Never 15 (78.9)
Ejaculation
Always 13 (68.4)
Often 3 (15.8)
Rarely 2 (10.5)
Never 1 (5.3)
Orgasm
Always 14 (73.7)
Often 3 (15.7)
Rarely 1 (5.3)
Never 1 (5.3)diagnosis was 64.7 years. Approximately 78.9% reported
never having presented with erectile dysfunction, and
73.7% had frequent orgasms before treatment of the
cancer. Finally, 68.4% of the patients considered that they
were misinformed about the impact of PB on sexuality.
Through the grid BASIC IDEA of Lazarus (6) and Cot-
traux et al. (7), we observed that the overall satisfaction
of sex was good, with 57.9% of patients declaring them-
selves satisfied by their current sexual life, and 47.4%
optimistic concerning the future. A total of 17 (89.5%)
patients were not concerned by the sexual performance.
It is interesting to note that 89.5% of patients considered
that PB did not result in any impairment of their sense
of masculinity. The look and the appearance of their penis
after PB were not a source of problems, confirming the
observations of Crook et al. (8). Fantasy production was
not interrupted by treatment because it is present in all
patients and abundant in 47.4% of them. Desire is also
maintained in the vast majority, although it is often less
intense. These results explain rather well that more than
60% of the patients believe that the PB has little or no
effect on their sexuality. Our investigation reveals that
the decision to stop sexual intercourse was, according to
the men, often a voluntary choice of the women. In
66.7% of the cases, the cause was the loss of the desire.
During the conversations, some men gave reasons for the
cessation of sexual intercourse such as age, cancer, and
its treatment.
However, among men aged older than 70 years, 42.9%
continued to be sexually active. This result reminds us that
there is no a limitation to the maintenance of a sexual life
(10). The problem of the lack of a partner, which is often
reported in series of elderly and aging populations, was
not observed here because all the patients were in a couple
or married. In a recent study in Anderson Cancer Center in
Houston, Huyghe et al. (11) had observed that the lack of
a sexual partner was less frequent as a cause of cessation
of sexuality in men than in women. The PB is not the only
treatment modality of localized early penile cancer. Among
the other treatments available for localized early disease,
there are partial penectomy, reconstruction glansectomy,
laser therapy, and glans resurfacing. All these treatments
may be disfiguring and may have an impact on the patient’s
sexual function, sexual intercourse, self-image, and self-
esteem. In this study, there were no patients who were
treated with partial amputation of the penis. It would be
interesting to use the same questionnaire in a surgical pop-
ulation to assess the real impact of the partial amputation of
the penis on sexuality. To date, most studies have focused
on sexual function in men treated with amputation of the
penis, but they have not explored the impact of treatment
on male behavior. They have quickly concluded a low
impact of partial amputations on sexual function. Romero
et al. (12), questioning a population of 18 men, reported
that 55.6% maintained erectile function during sexual inter-
course, and 72% maintained ejaculation and orgasm during
Table 4
Post-treatment sexual functions and behaviors
Parameters Classification N (%)
Sexual intercourse
Often 4 (21.1)
Sometimes 2 (10.5)
Rarely 4 (21.1)
Never 9 (47.3)
Erection
Often 8 (42.1)
Sometimes 5 (26.3)
Rarely 4 (21.1)
Never 2 (10.5)
Nocturnal/morning erection
Often 7 (36.7)
Sometimes 4 (21.1)
Rarely 4 (21.1)
Never 4 (21.1)
Quality of erections
Hard 4 (23.5)
Almost hard 6 (35.3)
Moderately hard 3 (17.8)
Soft 4 (23.5)
Masturbation
Very often 0 (0)
Often 0 (0)
Rarely 4 (21.1)
Never 15 (78.9)
Worry about sexuality
Very often 0 (0)
Often 0 (0)
Rarely 2 (10.5)
Never 17 (89.5)
Sensitivity of gland penis
No modification 10 (52.6)
Increase in sensitivity 5 (26.3)
Decrease in sensitivity 4 (21.1)
Size of penis
Suitable 16 (84.2)
Moderately suitable 3 (15.8)
Least inconvenient 0 (0)
Inconvenient 0 (0)
Appearance of penis
Suitable 14 (73.7)
Moderately suitable 3 (15.8)
Least inconvenient 2 (10.5)
Inconvenient 0 (0)
Fantasy
Very often 9 (47.4)
Often 6 (31.6)
Rarely 4 (21)
Never 0 (0)
Drugs for erection
Very often 0 (0)
Often 1 (5.2)
Rarely 2 (10.5)
Never 16 (84.2)
Satisfaction of future sexuality
Very satisfied 9 (47.4)
Satisfied 3 (15.8)
Moderately satisfied 5 (26.3)
Not much satisfied 2 (10.5)
Frequency of desire
Almost always/always 4 (21.1)
(Continued)
Table 4 (continued )
Parameters Classification N (%)
Most of the time 5 (26.2)
Sometimes 4 (21.1)
Rarely 4 (21.1)
Almost never/never 2 (10.5)
Intensity of desire
Very strong 1 (5.9)
Strong 2 (11.8)
Moderate 8 (47.1)
Mild 5 (29.3)
Almost nothing/nothing 1 (5.9)
Satisfaction of sexual life
Very satisfied 11 (57.9)
Satisfied 2 (10.5)
Moderately satisfied 3 (15.8)
Unsatisfied 3 (15.8)
Very unsatisfied 0 (0)
IIEF erectile domain
No ED (26e30) 7 (36.8)
Mild ED (22e25) 1 (5.3)
Mild-to-moderate ED (17e21) 1 (5.3)
Moderate ED (11e16) 0 (0)
Severe ED (1e10) 10 (52.6)
IIEF5 International index of erectile dysfunction; ED5 erectile
dysfunction.
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sexual intercourse before surgery. Among those with no
more sexual activity, the main reasons were the small size
of their penis and lack of glans. On a meta-analysis, Mad-
dineni et al. (13) found a greater impact of the partial
amputation of the penis, with an absence of sexual function
(assessed by IIEF score-15) in 36e67% of the patients. It is
interesting to compare the information provided by patients
treated surgically and PB for the sense of manliness. In
a series of 17 patients treated with partial (n5 11) or total
amputation (n5 4) of the penis, Ficarra et al. (14) had
found that emotional and mood disorders were common
in this population, with 35% with ‘‘problems in society,’’
29.5% pathologic anxiety, and 6% depression. The loss of
masculinity and the inability to penetrate is likely to cause
emotional stress, and it can therefore be expected that
patients treated with total or partial amputation of the penis
feel it to varying degrees. As in our study, 100% of the
patients said that their virility had not been altered; PB is
a treatment that probably has less psychological impact
than penile surgery. A therapeutic alternative for small
lesions of the penis is yttriumealuminumegarnet laser
ablation. In 2004, Windahl et al. (15) reported that of 10
of the 36 men treated by laser ablation who completed
the IIEF-15, 6 were not sexually active, whereas 4 scored
mild-to-moderate erectile dysfunction. However, using the
FugleMeyer Life satisfaction Check List scores, 50% were
shown to be satisfied with their sexual life. Taking the
series of patients treated in the same institution between
1986 and 2000, Windahl et al. (16) concluded that most
men treated with laser for localized cancer of the penis
Table 5
Nonsexual morbidity of treatment
Complications Score N (%)
Pain
Never 9 (47.4)
Rarely 5 (26.3)
Often 3 (15.8)
Very often 2 (10.5)
Bleeding
Never 12 (63.2)
Rarely 4 (21.1)
Often 2 (10.5)
Very often 1 (5.2)
Ulcerations
Never 11 (57.9)
Rarely 3 (15.8)
Often 1 (5.2)
Very often 4 (21.1)
Stenosis
Never 11 (57.9)
Rarely 3 (15.8)
Often 1 (5.2)
Very often 4 (21.1)
386 B. Delaunay et al. / Brachytherapy 13 (2014) 380e387resume to be sexually active at a level equivalent to that
before treatment, with good overall satisfaction concerning
their sexual life. However, these data are single centered,
and it seems premature to conclude the impact of laser
ablation.
Limitations
The first detailed analysis of the impact of PB on the
functions of the penis and sexual behavior has several limi-
tations. First, sexuality is an area highly dependent on
sociocultural elements. The findings on the impact of PB
of the penis on sex were obtained only from the French
men. Therefore, it may be difficult to extrapolate to other
cultures, including the Spanish Catalonian population. In
addition, because of the low incidence of this disease in Eu-
rope, the size of our study population was relatively small,
which limits our ability to achieve a detailed analysis,
including subgroups (young males, circumcised patients,
gay, and so on). In the absence of a control group, it is
impossible to compare the results of PB with other treat-
ments of localized cancer of the penis, in particular, partial
penectomy (17) and laser ablation and whether PB causes
less sexual dysfunction than the latter. For the method-
ology, although we have chosen the form of self-
administered questionnaire, followed by an interview so
that the patients are not influenced in their responses or
misunderstand the questions, we cannot rule out the subjec-
tivity of responses. In addition, the use of the IIEF in this
population is quite questionable because it is a poor score
that applies to a population with few penetrating sexual
reports. For this reason, we have completed a questionnaire
specifically designed for the study. However, the conclu-
sions drawn from it must be taken with caution; thisquestionnaire has not been previously subject to a validation
study. Therefore, these results should therefore be consid-
ered as preliminary data, which need to be confirmed with
a larger scale study.
Recently, a consensus guideline was developed between
the American Brachytherapy Society and Groupe Europeen
de Curietherapie/European Society for Therapeutic Radia-
tion and Oncology for the use of brachytherapy in the
primary management of carcinoma of the penis. The good
tumor control rates, acceptable morbidity, and functional
organ preservation warrant recommendation of brachyther-
apy as the initial treatment for invasive T1, T2, and selected
T3 penile cancers (18).Conclusion
After treatment, most patients reported that PB has little
or no effect on their sexuality. More than half of patients
remained sexually active after treatment and almost all
continued to have erections even if they were of lower
quality. There was little damage to body image and sense
of manliness. This information may play a key role in the
choice of penis cancer treatment leading to the maintenance
of a good sexual life. These results could also be the first
step in the development of targeted interventions on sexu-
ality in this population.References
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